Palbociclib as an Antitumor Drug: A License to Kill
Neoplastic cells are characterized by uncontrolled cell divisions caused by cell cycle dysregulation. Key regulatory proteins governing the transition from the G1 to the S phase are the CDK4 and CDK6 kinases, which are controlled by D-type cyclins. The CDK4/6 kinases enable the use of these proteins...
Saved in:
| Main Authors: | Agnieszka Łupicka-Słowik, Federica Cossu, Marcin Sieńczyk |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-11-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/29/22/5334 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents
by: Chao Wang, et al.
Published: (2022-12-01) -
PALBOCICLIB IN COMBINATION WITH HORMONE THERAPY FOR LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER: NEW HIGHLY EFFECTIVE STRATEGY OF DRUG TREATMENT
by: E. V. Artamonova
Published: (2017-09-01) -
Letrozole and palbociclib in advanced breast cancer: Outcome from cancer institute, Chennai
by: Vijay Gnanaguru, et al.
Published: (2020-01-01) -
CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
by: E. N. Imyanitov, et al.
Published: (2017-12-01) -
Enhancing palbociclib efficacy with low toxicity in breast cancer using polycaprolactone-based nanocarriers
by: Nastaran Zerang, et al.
Published: (2025-05-01)